NCT01628588已完成不适用
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 854
- 主要终点
- Change From Baseline in Intraocular Pressure (IOP)
研究概览
简要总结
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of primary open angle glaucoma or ocular hypertension
- •Prescribed Lumigan®
排除标准
- 未提供
研究组 & 干预措施
POAG or OHT
Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
干预措施: bimatoprost 0.01% (Drug)
结局指标
主要结局
Change From Baseline in Intraocular Pressure (IOP)
时间窗: Baseline, 14 Weeks
IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.
次要结局
- Patient Assessment of Tolerability Using a 4-Point Scale(14 Weeks)
- Physician Assessment of Tolerability Using a 4-Point Scale(14 Weeks)
- Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks(14 Weeks)
- Patients Who Will Continue Use of Lumigan® After 14 Weeks(14 Weeks)
研究者
相似试验
已完成
不适用
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Glaucoma, Open-AngleOcular HypertensionNCT01632423Allergan10,337
已完成
不适用
A Study of Bimatoprost 0.01% in the Clinical SettingGlaucoma, Primary Open AngleOcular HypertensionNCT01814761Allergan312
已完成
不适用
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Glaucoma, Open-AngleOcular HypertensionNCT01589510Allergan419
已完成
4 期
A Study of LUMIGAN® RC in the Clinical SettingGlaucoma, Primary Open AngleOcular HypertensionNCT01833741Allergan1,137
已完成
不适用
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Open-Angle GlaucomaOcular HypertensionNCT01568008Allergan933